share_log

B of A Securities Maintains Underperform on Sage Therapeutics, Lowers Price Target to $6

Benzinga ·  Oct 10 01:42  · Ratings

B of A Securities analyst Tazeen Ahmad maintains Sage Therapeutics (NASDAQ:SAGE) with a Underperform and lowers the price target from $11 to $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment